Recent News

• 05.18.2025 - Molgramostim Reduces Surfactant Background Burden and Number of Whole Lung Lavage Procedures in Patients with Autoimmune Pulmonary Alveolar Proteinosis (PAP): Results from the IMPALA-2 Phase 3 Clinical Trial
• 05.18.2025 - The Effects of Molgramostim on Respiratory Health-Related Quality of Life and Patient-Reported Outcomes in Patients with Autoimmune Pulmonary Alveolar Proteinosis (PAP)
• 04.16.2025 - Encore Presentation: Inhaled Molgramostim for the Treatment of Autoimmune Pulmonary Alveolar Proteinosis (aPAP) – Results from the IMPALA-2 Phase 3 Clinical Trial
• 04.10.2025 - Encore Presentation: Inhaled Molgramostim Improves Pulmonary Gas Exchange, Quality of Life, and Exercise Capacity in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

Recent Filings

• 05.15.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 05.13.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 04.25.2025 - DEF 14A Other definitive proxy statements
• 04.25.2025 - 10-K/A Annual report [Section 13 and 15(d), not S-K Item 405]
• 04.25.2025 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 04.25.2025 - ARS Annual Report to Security Holders
• 04.01.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.31.2025 - 8-K Current report
• 03.27.2025 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 03.27.2025 - SCHEDULE 13D/A General Statement of Acquisition of Beneficial Ownership